The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis

JAMA Neurology

Volumn 71, Issue 11, 2014, Pages 1421-1428

  Ireland, Sara J ^a   Guzman, Alyssa A ^a   O'Brien, Dina E ^a   Hughes, Samuel ^a   Greenberg, Benjamin ^a   Flores, Angela ^a   Graves, Donna ^a   Remington, Gina ^a   Frohman, Elliot M ^a   Davis, Laurie S ^a   Monson, Nancy L ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND; GLATIRAMER; INTERLEUKIN 10; INTERLEUKIN 6; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ADULT; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; TREATMENT DURATION; CLINICAL TRIAL; DRUG EFFECTS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; B-LYMPHOCYTES; CYTOKINES; FEMALE; GLATIRAMER ACETATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84919386274     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1472     Document Type: Article

References (38)

1. Ireland SJ, BlazekM, Harp CT, et al. Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity. Autoimmunity. 2012;45(5):400-414.
2. Bar-Or A, Fawaz L, Fan B, et al. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67(4):452-461.
3. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J Exp Med. 2012; 209(5):1001-1010.
4. KalaM, Rhodes SN, Piao WH, Shi FD, Campagnolo DI, Vollmer TL. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010; 221(1):136-145.
5. Begum-Haque S, Christy M, Ochoa-Reparaz J, et al. Augmentation of regulatory B cell activity in experimental allergic encephalomyelitis by glatiramer acetate. J Neuroimmunol. 2011;232(1-2): 136-144.
6. Begum-Haque S, Sharma A, Christy M, et al. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010;219(1-2):47-53.
7. Vieira PL, Heystek HC,Wormmeester J, Wierenga EA, KapsenbergML. Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol. 2003;170(9):4483-4488.
8. Duda PW, Schmied MC, Cook SL, Krieger JI, Hafler DA. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest. 2000; 105(7):967-976.
9. Hong J, Li N, Zhang X, Zheng B, Zhang JZ. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci U S A. 2005;102 (18):6449-6454.
10. Tennakoon DK, Mehta RS, Ortega SB, Bhoj V, Racke MK, Karandikar NJ. Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis. J Immunol. 2006;176(11):7119-7129.
11. Karandikar NJ, Crawford MP, Yan X, et al. Glatiramer acetate (Copaxone) therapy induces CD8+ T cell responses in patients with multiple sclerosis. J Clin Invest. 2002;109(5):641-649.
12. Fridkis-Hareli M, Teitelbaum D, Pecht I, Arnon R, Sela M. Binding of copolymer 1 andmyelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells. Int Immunol. 1997;9 (7):925-934.
13. Fridkis-HareliM, Teitelbaum D, Gurevich E, et al. Direct binding ofmyelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells-specificity and promiscuity. Proc Natl Acad Sci U S A. 1994;91(11):4872-4876.
14. Aharoni R, Teitelbaum D, Arnon R, SelaM. Copolymer 1 acts against the immunodominant epitope 82-100 ofmyelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A. 1999;96(2):634-639.
15. Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172(11):7144-7153.
16. Weber MS, StarckM,Wagenpfeil S, Meinl E, Hohlfeld R, Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127(pt 6):1370-1378.
17. Cerutti A, ColsM, Puga I. Activation of B cells by non-canonical helper signals. EMBO Rep. 2012;13 (9):798-810.
18. Wei C, Jung J, Sanz I. OMIP-003: phenotypic analysis of human memory B cells. Cytometry A. 2011;79(11):894-896.
19. Dörner T, Lipsky PE. Correlation of circulating CD27high plasma cells and disease activity in systemic lupus erythematosus. Lupus. 2004;13(5): 283-289.
20. Bouaziz JD, Calbo S, Maho-Vaillant M, et al. IL-10 produced by activated human B cells regulates CD4+T-cell activation in vitro. Eur J Immunol. 2010; 40(10):2686-2691.
21. Blair PA, Noreña LY, Flores-Borja F, et al. CD19+CD24hiCD38hi B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity. 2010;32(1):129-140.
22. Flores-Borja F, Bosma A, Ng D, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013;5(173):173ra123. doi:10.1126 /scitranslmed.3005407.
23. Iwata Y, Matsushita T, HorikawaM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011;117(2):530-541.
24. Maseda D, Smith SH, DiLillo DJ, et al. Regulatory B10 cells differentiate into antibody-secreting cells after transient IL-10 production in vivo. J Immunol. 2012;188(3):1036-1048.
25. ZhangW, Shi Q, Xu X, et al. Aberrant CD40-induced NF-êB activation in human lupus B lymphocytes. PLoS One. 2012;7(8):e41644. doi:10.1371/journal.pone.0041644.
26. Kroese FG, Abdulahad WH, Haacke E, Bos NA, Vissink A, Bootsma H. B-cell hyperactivity in primary Sjögren's syndrome. Expert Rev Clin Immunol. 2014;10(4):483-499.
27. Bishop GA. The many faces of CD40: multiple roles in normal immunity and disease. Semin Immunol. 2009;21(5):255-256.
28. Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol. 2009;647:8-36.
29. Achiron A, Feldman A, GurevichM. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers. 2009;27 (2):63-73.
30. Bakshi S, Chalifa-Caspi V, Plaschkes I, Perevozkin I, GurevichM, Schwartz R. Gene expression analysis reveals functional pathways of glatiramer acetate activation. Expert Opin Ther Targets. 2013;17(4):351-362.
31. Harp CT, Ireland S, Davis LS, et al. Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4+T-cell proliferation and IFN-ã production in response tomyelin basic protein andmyelin oligodendrocyte glycoprotein. Eur J Immunol. 2010; 40(10):2942-2956.
32. Suen WE, Bergman CM, Hjelmström P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med. 1997;186(8): 1233-1240.
33. Molnarfi N, Schulze-Topphoff U,Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent ofmyelin-specific antibodies. J ExpMed. 2013;210(13):2921-2937.
34. Yoshizaki A, Miyagaki T, DiLillo DJ, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264-268.
35. Correale J, Farez M, Razzitte G. Helminth infections associated with multiple sclerosis induce regulatory B cells. Ann Neurol. 2008;64(2):187-199.
36. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003;101(11):4500-4504.
37. Teitelbaum D, Brenner T, Abramsky O, Aharoni R, SelaM, Arnon R. Antibodies to glatiramer acetate do not interfere with its biological functions and therapeutic efficacy. Mult Scler. 2003;9(6):592-599.
38. Bomprezzi R, Schafer R, Reese V,Misra A, Vollmer TL, KalaM. Glatiramer acetate-specific antibody titres in patients with relapsing/remitting multiple sclerosis and in experimental autoimmune encephalomyelitis. Scand J Immunol. 2011;74(3): 219-226.